David N. Gordon - 13 Jul 2021 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Chief Medical Officer
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 13 Jul 2021
Net transactions value: -$44,675
Form type: 4
Filing time: 14 Jul 2021, 17:32:17 UTC
Previous filing: 07 Jul 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Sale	$44,675	-2,631	-1.8%	$16.98	147,447	13 Jul 2021	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on July 2, 2021 pursuant to preexisting sell-to-cover elections.
F2	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.9755 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

Shares sold to satisfy withholding tax obligations upon the delivery of shares of common stock for restricted stock units that vested on July 2, 2021 pursuant to preexisting sell-to-cover elections.

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $16.9755 to $17.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.